Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.
Actively Recruiting
Researchers are evaluating the efficacy and safety of milsaperidone as an add-on treatment for patients with Major Depressive Disorder MDD who have not responded adequately to current antidepressant therapy. This phase 3, randomized, double-blind, placebo-controlled study aims to compare milsaperidone with a placebo to better understand its potential benefits and risks in this patient population. Participants will be randomly assigned to receive either oral milsaperidone or a matching placebo. The study uses a parallel design and involves multiple centers. The treatment period lasts 6 weeks, during which participants take the assigned oral medication as adjunctive therapy to their existing antidepressant regimen. During the study, participants will be closely monitored with regular assessments including the Montgomery-Asberg Depression Rating Scale MADRS to measure changes in depressive symptoms from baseline. Safety and tolerability will also be evaluated throughout the trial. The total duration of participation corresponds with the 6-week treatment and ongoing safety assessments, concluding by March 2028.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.
Actively Recruiting
Researchers are evaluating the effectiveness of NBI-1065845 compared with a placebo as an additional treatment to improve symptoms in adults with major depressive disorder MDD. The study focuses on participants who have recurrent moderate to severe MDD or persistent depressive disorder and who have not responded adequately to oral antidepressants in their current episode. This Phase 3 trial is designed to assess both the efficacy and safety of this investigational drug. Participants will be randomly assigned to receive either NBI-1065845 or a matching placebo, both administered orally once a day. The study is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment duration lasts 56 days, during which participants continue their current oral antidepressant medication at the same dose. The study uses a parallel design with two groups receiving either the drug or placebo. During the trial, participants will be assessed at baseline and at Day 56 using several scales to measure changes in depression severity and disability. These include the Montgomery-5sberg Depression Rating Scale MADRS, the Sheehan Disability Scale SDS, and the Clinical Global Impression-Severity Scale CGI-S. Participants must comply with all study procedures and restrictions, and their safety and response to treatment will be closely monitored throughout the study period, which ends in July 2027.
Actively Recruiting
Researchers are evaluating the drug ITI-1284 as a monotherapy treatment in patients diagnosed with moderate to severe Generalized Anxiety Disorder GAD who have not responded adequately to previous GAD treatments. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to assess the efficacy, safety, and tolerability of ITI-1284 in this patient population. Participants are randomly assigned to one of three groups ITI-1284 10 mg tablet, ITI-1284 20 mg tablet, or a matching placebo, all taken once daily by sublingual administration. The study compares these doses to placebo over a treatment period, with assessments planned at Week 6. During the study, participants will be monitored for changes in anxiety using the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S at Week 6. Safety and tolerability will also be evaluated. The total duration includes the screening, treatment, and follow-up periods leading up to the primary completion date in October 2027 and study completion in July 2028.
Actively Recruiting
Researchers are evaluating lumateperone as an additional treatment for adults aged 18 to 65 years with major depressive disorder MDD who have not responded adequately to current antidepressant treatments. This phase 3, multicenter study is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy and safety of lumateperone in this population. The study includes patients with moderate to severe depression diagnosed according to DSM-5 criteria, including those with psychotic features. Participants will be randomly assigned to receive either lumateperone 42 mg capsules or matching placebo capsules once daily for six weeks during the double-blind treatment period. The study consists of three distinct periods an initial screening lasting up to two weeks to determine eligibility, the six-week treatment phase with daily medication, and a one-week safety follow-up after the last dose to monitor any adverse effects. During the study, participants will undergo assessments including depression rating scales such as the Montgomery-Asberg Depression Rating Scale MADRS and Clinical Global Impression Scale-Severity. Safety evaluations will be conducted throughout, including a follow-up visit about one week after treatment ends. The total participation time may last up to nine weeks, encompassing screening, treatment, and safety monitoring.